Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2021-10-04
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional therapy
Length of period: 2 weeks
Conventional therapy
Conventional therapy specifies the neurorehabilitation therapy as applied as regular treatment.
Therapy assisted by a humanoid robot (E-BRAiN)
Length of period: 2 weeks Fixed dose: 10 therapy sessions with E-BRAiN
E-BRAiN therapy
The therapy system E-BRAiN is a purpose-built therapy system using a socially interactive humanoid robot and provides individualised therapy for arm rehabilitation based on the evidence-based therapies arm basis training, arm ability training, or mirror therapy for arm rehabilitation (paresis) or neurovisual training (neglect).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E-BRAiN therapy
The therapy system E-BRAiN is a purpose-built therapy system using a socially interactive humanoid robot and provides individualised therapy for arm rehabilitation based on the evidence-based therapies arm basis training, arm ability training, or mirror therapy for arm rehabilitation (paresis) or neurovisual training (neglect).
Conventional therapy
Conventional therapy specifies the neurorehabilitation therapy as applied as regular treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stroke (ischemic stroke, non-traumatic intracerebral haemorrhage, subarachnoidal haemorrhage)
* Incomplete arm paresis (Motricity Index, arm score \>1 \[Min\] and \< 100 \[Max\]) or
* Visuospatial neglect (clinical signs and NET subtest "star cancellation" score \< 50)
* Candidate able to consent and provides informed consent or
* legal representative provides informed consent
Exclusion Criteria
* Obliged to live in an institution by law or public authority
* With case presentation arm paresis: another condition that causes arm paresis is present
* With case presentation visuospatial neglect: another condition that causes a relevant visual-perceptual deficit that cannot be compensated is present; exception: homonymous visual field deficits are not an exclusion criterion
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BDH-Klinik Greifswald
UNKNOWN
University Medicine Greifswald
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Platz, Prof.Dr.med.
Role: PRINCIPAL_INVESTIGATOR
Head, Neurorehabilitation Research Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsmedizin Greifswald
Greifswald, , Germany
BDH-Klinik Greifswald
Greifswald, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Thomas Platz, Prof.Dr.med.
Role: primary
Thomas Platz, Prof.Dr.med.
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Research web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIV-21-01-035629
Identifier Type: REGISTRY
Identifier Source: secondary_id
202101E-BRAiN
Identifier Type: -
Identifier Source: org_study_id